| __timestamp | BioCryst Pharmaceuticals, Inc. | Incyte Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 51796000 | 347523000 |
| Thursday, January 1, 2015 | 72758000 | 479514000 |
| Friday, January 1, 2016 | 61008000 | 581861000 |
| Sunday, January 1, 2017 | 66962000 | 1326361000 |
| Monday, January 1, 2018 | 84888000 | 1197957000 |
| Tuesday, January 1, 2019 | 107068000 | 1154111000 |
| Wednesday, January 1, 2020 | 122964000 | 2215942000 |
| Friday, January 1, 2021 | 208808000 | 1458179000 |
| Saturday, January 1, 2022 | 253297000 | 1585936000 |
| Sunday, January 1, 2023 | 216566000 | 1627594000 |
| Monday, January 1, 2024 | 2606848000 |
Unleashing insights
In the ever-evolving world of biotechnology, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, Incyte Corporation and BioCryst Pharmaceuticals, Inc. have demonstrated contrasting approaches to R&D investment. From 2014 to 2023, Incyte consistently outspent BioCryst, with its R&D expenses peaking at approximately $1.6 billion in 2023, a staggering 650% increase from 2014. In contrast, BioCryst's R&D spending grew by about 318% over the same period, reaching around $217 million in 2023.
This disparity highlights Incyte's aggressive investment strategy, which may be linked to its broader pipeline and market ambitions. Meanwhile, BioCryst's more modest spending reflects a focused approach, potentially targeting niche markets. As the biotech landscape continues to shift, these spending patterns offer valuable insights into each company's strategic priorities and potential future breakthroughs.
BeiGene, Ltd. vs Incyte Corporation: Strategic Focus on R&D Spending
Comparing Innovation Spending: Incyte Corporation and Viatris Inc.
R&D Insights: How Incyte Corporation and Amneal Pharmaceuticals, Inc. Allocate Funds
Incyte Corporation vs Soleno Therapeutics, Inc.: Strategic Focus on R&D Spending
Incyte Corporation or Vericel Corporation: Who Invests More in Innovation?
Research and Development: Comparing Key Metrics for Incyte Corporation and Geron Corporation
Who Prioritizes Innovation? R&D Spending Compared for Sarepta Therapeutics, Inc. and BioCryst Pharmaceuticals, Inc.
Research and Development Investment: Ascendis Pharma A/S vs BioCryst Pharmaceuticals, Inc.
Research and Development Expenses Breakdown: Rhythm Pharmaceuticals, Inc. vs BioCryst Pharmaceuticals, Inc.
Research and Development: Comparing Key Metrics for PTC Therapeutics, Inc. and BioCryst Pharmaceuticals, Inc.
Protagonist Therapeutics, Inc. vs BioCryst Pharmaceuticals, Inc.: Strategic Focus on R&D Spending
Analyzing R&D Budgets: MannKind Corporation vs BioCryst Pharmaceuticals, Inc.